Pharma companies and patient groups seek to exempt orphan drugs from Colorado pricing limits
Strategic angle: A bill is moving through the Colorado legislature that would exempt orphan drugs from pricing caps that might be pursued by the state.
Medical supplies are stuck in Dubai, as clinics around the world face shortages
Strategic angle: The war in Iran has slowed down international shipping, much of which contains medical and humanitarian goods destined for Asia and Africa.
Polymers Built Inside the Body Allow On-Demand Brain Control
Strategic angle: Innovative blood-catalyzed chemistry paves the way for advanced medical applications.
Briefing: Shingles can hit younger than you think. The vaccine can prevent excruciating pain
Strategic angle: A reactivation of the virus that causes chickenpox, the illness can be miserable. Here's what to know about early warning signs, long-term symptoms and some surprising news about the vaccine.
China Executes French National Convicted in 2010 for Drug Trafficking
France's foreign ministry expresses consternation over the execution of a French citizen sentenced to death in China.
Briefing: Biotech Investors Urge Trump Amid M&A Activity
Strategic angle: Smaller biotechs negotiate with the White House while addressing the trust gap in medicine.
Briefing: Opinion: My patient would rather take a peptide than a statin. That reveals an uncomfortable truth in medicine
Strategic angle: “The volume of evidence behind a therapy has become inversely correlated with public trust in it,” writes Vikas Patel.
Briefing: Supreme Court conversion therapy decision could ripple through medicine
Strategic angle: A Supreme Court ruling this week on gender and sexuality 'conversion therapy' could narrow the authority of state medical boards over care involving speech.
Briefing: Proposed ‘preclinical obesity’ diagnosis ignites global debate among experts
Strategic angle: A new way to define obesity aims to sharpen the diagnosis. Critics warn it could delay care, exclude diabetes, and deepen inequities in accessing treatment.
Briefing: The FDA approves a new obesity pill, giving patients another option
Strategic angle: The daily pill called Foundayo got a fast track through the Food and Drug Administration.
Briefing: Novo’s subscription model raises questions about pharma-telehealth tie-ups
Strategic angle: A delayed FDA decision for Orca Bio, new questions about pharma-telehealth tie-ups, and more
Briefing: Can a psychedelic ‘coach’ make ketamine therapy even more effective?
Strategic angle: A new study explores whether incorporating psychotherapy with ketamine treatment enhances its effectiveness.
Briefing: Opinion: Medical marijuana should not be recommended for PTSD, anxiety, or depression
Strategic angle: “Rigorously derived evidence for the medical efficacy of marijuana is thin,” writes Kevin Sabet.
Briefing: SimCells successfully target and kill drug-resistant bacteria
Strategic angle: A breakthrough in the fight against superbugs and antimicrobial resistance.
Briefing: Pharma Delays Launches in Europe Amid U.S. Pressure
Strategic angle: Drugmakers are postponing the release of new medicines in Europe due to shifting pricing policies and pressures from the U.S.
Briefing: Here’s Why Fresenius Medical Care AG (FMS) Remains Attractive
Strategic angle: Here’s Why Fresenius Medical Care AG (FMS) Remains Attractive
Briefing: Pharma giant Takeda to lay off nearly 250 workers in latest job cutting
Strategic angle: Takeda Pharmaceuticals, the largest biopharma employer in Mass., will lay off 250 workers in Cambridge beginning in July.
Briefing: Doctors Without Borders calls Gilead ‘unconscionable’ for refusing to sell HIV prevention drug
Strategic angle: The organization criticized Gilead Sciences after months of negotiations for a limited supply of lenacapavir.
Briefing: Biogen Lupus Drug Shows Promise in Mid-Stage Study
Strategic angle: The drug demonstrates improved skin clearance, marking a significant advancement in lupus treatment.
Briefing: Trump Pushes Drug Pricing Policy Amid Biotech Developments
Strategic angle: The White House shares legislative text on drug pricing with major pharmaceutical companies.